Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced four abstracts showcasing data from its KER-050 and ALK2 hematology programs at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. Key presentations include details on KER-050's effects on hemoglobin and platelet increases, red blood cell production in cynomolgus monkeys, and its potential for treating ineffective erythropoiesis. The company plans to commence Phase 2 trials for KER-050 in patients with myelodysplastic syndromes and myelofibrosis later this year.